Afaxor 75/Afaxor 150

Afaxor 75/Afaxor 150

venlafaxine

Manufacturer:

Pell Tech Healthcare

Distributor:

Emcure Pharma

Marketer:

MedEthix
Concise Prescribing Info
Contents
Venlafaxine HCl
Indications/Uses
Major depressive disorder, generalized anxiety disorder (GAD), social anxiety disorder (social phobia).
Dosage/Direction for Use
Major depressive disorder/GAD Initially 75 mg/day as single dose. Moderately depressed outpatients Initially 75 mg/day. New patients adjusting to medication 37.5 mg/day for 4-7 days, increasing to 75 mg/day. Max: 225 mg/day. Dose increases in increments up to 75 mg/day as needed & should be made at interval not <4 days. Social anxiety disorder (social phobia) 75 mg/day. Panic disorder Initially 37.5 mg/day for 7 days. Outpatients w/ panic disorder Initially 37.5 mg/day for 7 days followed by 75 mg/day & subsequent wkly dose increases of 75 mg/day to a max of 225 mg/day. Dose increases should be up to 75 mg/day as needed & should be made at intervals not <7 days.
Administration
Should be taken with food: Take at approx same time each day. Swallow whole, do not divide/chew/crush/place in water. May open cap & sprinkle contents on a spoonful of applesauce and swallow immediately w/o chewing followed by a glass of water.
Contraindications
Hypersensitivity. Concomitant use w/ MAOIs. Increased risk of serotonin syndrome w/ linezolid or IV methylene blue.
Special Precautions
Clinical worsening of depression, suicidality & unusual changes in behavior especially during initial few mth of course drug therapy or at times of dose changes. Not approved use for treating bipolar depression. Development of serotonin syndrome due to concomitant use w/ serotonergic drugs. Angle-closure glaucoma. Sustained HTN. Monitor for discontinuation symptoms due to abrupt discontinuation & dose changes. Insomnia & nervousness; changes in wt; hyponatremia; ILD & eosinophilic pneumonia. Patients w/ history of mania; hyperthyroidism, heart failure or recent MI. Co-administration w/ wt loss agents is not recommended. Abnormal bleeding in concomitant use w/ NSAIDS, aspirin. Renal impairment (GFR 10-70 mL/min) or liver cirrhosis. Pregnancy during 3rd trimester. Lactation. Wt gain for childn <12 yr. Childn. Elderly.
Adverse Reactions
Chest pain substernal, chills, fever, neck pain; migraine, tachycardia; increased appetite; ecchymosis; edema, wt. gain; amnesia, confusion, depersonalization, hypesthesia, abnormal thinking, vertigo; increased cough, dyspnea; pruritus; abnormality of accommodation, mydriasis, taste perversion; albuminuria, impaired urination.
Drug Interactions
Alcohol, cimetidine, diazepam, haloperidol, lithium, imipramine, CNS active drugs, triptans. Potentiate risk of bleeding w/ NSAIDs, aspirin, warfarin. Increase plasma conc of metoprolol. Increase AUC of risperidone. Decrease AUC of indinavir. Increased risk of QTc prolongation w/ antipsychotics & antibiotics. False +ve urine immunoassay screening test for PCP & amphetamine.
MIMS Class
Antidepressants
ATC Classification
N06AX16 - venlafaxine ; Belongs to the class of other antidepressants.
Presentation/Packing
Form
Afaxor 150 SR cap 150 mg
Packing/Price
30's
Form
Afaxor 75 SR cap 75 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in